MeiraGTx Holdings: Promising Growth Potential with Strategic Manufacturing and Positive ...
Alec Stranahan, an analyst from Bank of America Securities, maintained the Buy rating on Meiragtx Holdings (MGTX – Research Report). The ...
precisionmedicineonline18 小时
MeiraGTx to Discuss Parkinson's Gene Therapy Data With Regulators, Planning Phase III Trial
The company said the latest positive safety, tolerability, and efficacy data will underpin discussions with regulators in the US, Europe, and Japan.
MeiraGTx (MGTX) Surges 14.9%: Is This an Indication of Further Gains?
MeiraGTx (MGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...
Zacks.com on MSN20 小时
MGTX Stock Up on Upbeat Efficacy Data From Parkinson's Disease Study
MeiraGTx Holdings’ MGTX clinical bridging study of its gene therapy candidate, AAV-GAD, for treating Parkinson’s disease (PD) ...
MeiraGTx Holdings Reports Promising Parkinson’s Therapy Results
MeiraGTx Holdings has unveiled promising results from its clinical bridging study of AAV-GAD, a gene therapy for Parkinson’s ...
bovnews23 小时
MeiraGTx Holdings PLC (MGTX) Stock: Greater Than Its Current Valuation?
On Tuesday, MeiraGTx Holdings PLC (MGTX) stock saw a modest uptick, ending the day at $5.33 which represents a slight increase of $0.69 or 14.87% from the prior close of $4.64. The stock opened at $5.